Clinical Trial Update: Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma Patients [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial assessing pembrolizumab plus lenvatinib in second- and third-line malignant pleural mesothelioma, with the study currently acti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Pleural Mesothelioma

Drugs mentioned

• Lenvatinib (lenvatinib)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: The Netherlands Cancer Institute | Conditions: Mesotheliomas Pleural | Phase 2 | Status: ACTIVE_NOT_RECRUITING